Search Results
Showing Results for temozolomide
In the latest edition of touchREVIEWS in Oncology & Haematology, we are pleased to present a collection of articles that delve into the latest research and advancements in the field. From innovative therapies and genetic treatments to analyses of digital ...
The management of children with diffuse midline gliomas (DMG) and other paediatric high-grade gliomas (pHGG) continue to present one of the most difficult challenges facing paediatric oncologists, characterized by poor patient outcomes.1Â Standard of care therapy, which includes a maximal ...
Adult-type diffuse low-glade gliomas (LGGs) (World Health Organization [WHO] grade 2) represent 5–10% of all primary brain tumours.1 The median age of onset is in the third and fourth decades of life. Common clinical presentations include seizures, focal neurological deficits, and new-onset ...
Neuroendocrine neoplasms (NENs) comprise a heterogenous group of malignancies with diverse clinical behaviour determined by tumour characteristics such as grade, differentiation and primary tumour origin.1 While neuroendocrine carcinomas are poorly differentiated aggressive malignancies, well-differentiated neuroendocrine tumours (NETs) tend to be ...
Ocular melanoma represents a small subset of total melanoma cases. Approximately 3.7% of melanoma cases are ocular,1 and slightly over 80% of ocular melanomas are classified as uveal.1,2 Most uveal melanomas occur from the choroid, with the remainder developing from the ciliary ...
Cancer immunotherapy has come of age and has successfully been implemented as the standard of care in a number of oncologic indications.1 Antibodies targeting cancer-associated antigens on the tumour cell, such as CD20, constituted the first wave of immunotherapies leading ...
The current treatment for most cancerous growths consists of surgery, radio- and chemotherapy or combinations. The underlying rationales for those options remains, therefore, virtually unaltered since, respectively, the times of the Pharaohs.1 Emil Grubbe irradiated the first breast cancer in 18962 ...
Case Presentation A 64-year-old male presented with a 1-month history of progressively worsening headaches. He had no other central neurological symptoms, including ocular symptoms, and examination of the central and peripheral nervous system was normal. Physical examination did not reveal ...
Glioblastoma Multiforme Glioblastoma multiforme (GBM) is the most malignant of the primary brain cancers with only about 12 % of patients surviving beyond 36 months (longterm survivors).1–4 Most GBMs are heterogeneous in cellular composition consisting of tumor stem cells, malignantly transformed mesenchymal cells, ...
Melanoma is the fifth leading cancer in men and the seventh in women. The incidence is increasing and it is estimated that in 2012 76,250 people in the US were diagnosed with melanoma of the skin and 9,180 died of the disease.1The ...
Pancreatic neuroendocrine tumours (pNETs), also known as islet cell tumours, arise from the pancreatic islet of Langerhans and can be divided into functioning and non-functioning tumours based on whether they are associated with hormonal syndromes caused by excess hormone or ...
Abstract Advances in our understanding of the molecular basis of cancer have shown that biomarkers can help guide therapy in a growing number of cancer types and that targeted therapies are becoming increasingly integral to cancer management. However, how to ...
In 1971, Folkman formulated the hypothesis that tumour growth and metastasis are angiogenesis-dependent events. 1 Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis. VEGF levels have been demonstrated to be elevated in choroidal melanoma.2,3 However, the use of anti-angiogenic ...
In 2010, prostate cancer was the most commonly found malignant cancer in men, comprising 28 % of all new cancer cases.1 In the US, it is the second leading cause of cancer death in men, with annual mortality rates of approximately 30,000 deaths per ...
The European Organisation for Research and Treatment of Cancer (EORTC) was founded in 1962 as an international organisation under Belgian law by eminent European oncologists working in the main areas of cancer research. Originally named the Groupe Européen de Chimiothé...
The purpose of this article is to review the current treatment options for patients with glioblastoma (GBM). The current standard of care involves maximal safe surgical resection followed by concurrent chemotherapy with radiation followed by adjuvant chemotherapy. Although level 1 evidence ...
The treatment of patients with glioblastoma multiforme (GBM) is considered to be a palliative venture with no hope of cure. Traditionally, patients are treated with maximal surgical resection based on the premise that, although surgery is not a curative procedure, ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
